Results 81 to 90 of about 680,317 (306)
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec +6 more
wiley +1 more source
A Case of Autosomal Dominant Osteopetrosis Type 2 with a CLCN7 Gene Mutation
JCRPE, 2019 Osteopetrosis is a rare genetic disease characterized by increased bone density and bone fractures due to defective osteoclast function. Autosomal dominant osteopetrosis type 2 (ADO-2), Albers-Schonberg disease, is characterized by the sclerosis of bones,
Sol Kang +4 more
doaj +1 more source
Zaporožskij Medicinskij Žurnal, 2017 Purpose of the work – to investigate the possible contribution of aldosterone synthetase gene (CYP11B2) polymorphism to the disease course and structural parameters of LV in patients with coronary heart disease, postinfarction cardiosclerosis ...
M. N. Dolzhenko +2 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Cognitive impairment is a common non‐motor symptom in Multiple Sclerosis (MS), negatively affecting autonomy and Quality of Life (QoL). Innovative rehabilitation strategies, such as semi‐immersive virtual reality (VR) and computerized cognitive training (CCT), may offer advantages over traditional cognitive rehabilitation (TCR ...
Maria Grazia Maggio +8 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Participant recruitment into a randomised controlled trial of exercise therapy for people with multiple sclerosis [PDF]
, 2015 Background: The success of a clinical trial is often dependant on whether recruitment targets can be met in the required time frame. Despite an increase in research into the benefits of exercise in people with multiple sclerosis (PwMS), no trial has ...
Woodroofe, Nicola +15 more
core +1 more source
Insights on the Use of α-Lipoic Acid for Therapeutic Purposes
Biomolecules, 2019 α-lipoic acid (ALA, thioctic acid) is an organosulfur component produced from plants, animals, and humans. It has various properties, among them great antioxidant potential and is widely used as a racemic drug for diabetic polyneuropathy-associated pain ...
Bahare Salehi +12 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background and Purpose White matter hyperintensities (WMH) are a core neuroimaging marker of cerebral small vessel disease (CSVD). Sleep apnoea (SA) is a recognized vascular risk factor, but its associations with regional WMH burden, short‐interval WMH change and cognitive performance in population‐based cohorts remain incompletely defined. We
Peng Cheng +4 more
wiley +1 more source
International Archives of OtorhinolaryngologyIntroduction Various factors have been reported to affect the rates of success after tympanoplasty, among them, myringosclerosis. However, there are few studies focusing only on the effect of myringosclerotic plaque removal on tympanoplasty ...
Ayaz Rehman +5 more
doaj +1 more source
Craniometaphyseal dysplasia: A rare case in radiologic perspective
Journal of Indian Academy of Oral Medicine and Radiology, 2014 Craniometaphyseal dysplasia (CMD) is a very rare bone disorder of unknown etiology. It is characterized by sclerosis of the skull, craniofacial bones and even extremities.
Simi Thankappan, Sherin Nair
doaj +1 more source